MKMark Kalisz

Mark Kalisz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mark Kalisz has a total of 56 co-authors. Here are the top co-authors by number of shared publications:

  • Edgar Bernardo

    Bioinformatics and Genomics Program Centre for Genomic Regulation (CRG) The Barcelona Institute of Science and Technology (BIST) Barcelona Spain

    2 shared publications
  • Eva Vaquero

    CiberEHD Institut de Malalties Digestives i Metabòliques Hospital Clínic IDIBAPS Barcelona Spain

    2 shared publications
  • Francisco Xavier Real

    Epithelial Carcinogenesis Group, Molecular Oncology Programme, Centro Nacional de Investigaciones Oncológicas, Madrid, Spain

    2 shared publications
  • Irene Esposito

    Department of Surgery Heinrich‐Heine University and University Hospital of Düsseldorf Düsseldorf Germany

    2 shared publications
  • Irene Millán

    Epithelial Carcinogenesis Group Spanish National Cancer Research Centre‐CNIO Madrid Spain

    2 shared publications
  • Jorge Ferrer

    Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain

    2 shared publications

Latest Publications

  • Open Access

    Nerve growth factor receptor identifies a basal subpopulation linked to poor prognosis and reduced immunotherapy responses in bladder cancer

    by Juan García-Agulló, Vanesa Santos, Mark Kalisz, Miriam Marqués, Elena Andrada, Catalina Berca, María Ramal, Jaime Martínez de Villarreal, Manuel Pérez-Martínez, Markus Eckstein, et al.

    Purpose: Bladder cancer (BLCA) is a heterogeneous tumor type. Only one third of muscle-invasive (MIBC) patients respond to immune checkpoint inhibitors (ICIs). Reliable resistance markers are needed to guide clinical decisions. We investigated the nerve growth factor receptor (NGFR) in BLCA and analyzed its correlation with disease progression and response to immunotherapy. Experimental Design: We analyzed NGFR expression in BLCA cell lines, organoids, mouse models and patient samples. The cohorts used were The Cancer Genome Atlas (TCGA), enriched in muscle-invasive bladder cancer (MIBC) (n=407); IMvigor210, representing MIBC patients treated with ICIs (n=348); and UROMOL2, as a non-muscle-invasive bladder cancer (NMIBC)-specific cohort (n=535). IMvigor010 was also included (n=728). Patients were stratified by NGFR expression quartiles. We analyzed survival and tumor subtypes and performed stromal deconvolution and functional profiling. We assessed stemness- and invasion-related features in SCaBER cells. Results: NGFR marks a basal tumor cell subcluster and is independently associated with poor prognosis in TCGA and IMvigor210. NGFR-high tumors show stromal content enriched in cancer-associated fibroblasts, lower neoantigen burden, higher CD8 + T effector signature together with an immune-excluded phenotype, and a CAF-specific TGFβ signature. In the immunotherapy-treated cohort, high NGFR expression was also associated with poorer outcome. Functionally, NGFR appears to promote a stem-like/pro-invasive program in BLCA cells. Conclusions: NGFR identifies a basal-like BLCA subpopulation linked to poor survival, while its association with immunotherapy response requires further validation. In addition, our in vitro analyses support a role of NGFR in stem-like and invasive traits, highlighting its relevance as a biomarker in BLCA.

  • Open Access

    The GATA3 X308_Splice breast cancer mutation is a hormone context-dependent oncogenic driver

    by Natascha Hruschka, Mark Kalisz, Maria Subijana, Osvaldo Graña-Castro, Francisco Del Cano-Ochoa, Laia Paré Brunet, Igor Chernukhin, Ana Sagrera, Aurelien De Reynies, Bernhard Kloesch, et al.

    As the catalog of oncogenic driver mutations is expanding, it becomes clear that alterations in a given gene might have different functions and should not be lumped into one class. The transcription factor GATA3 is a paradigm of this. We investigated the functions of the most common GATA3 mutation (X308_Splice) and five additional mutations, which converge into a neoprotein that we called “neoGATA3,” associated with excellent prognosis in patients. Analysis of available molecular data from >3000 breast cancer patients revealed a dysregulation of the ER-dependent transcriptional response in tumors carrying neoGATA3-generating mutations. Mechanistic studies in vitro showed that neoGATA3 interferes with the transcriptional programs controlled by estrogen and progesterone receptors, without fully abrogating them. ChIP-Seq analysis indicated that ER binding is reduced in neoGATA3-expressing cells, especially at distal regions, suggesting that neoGATA3 interferes with the fine tuning of ER-dependent gene expression. This has opposite outputs in distinct hormonal context, having pro- or anti-proliferative effects, depending on the estrogen/progesterone ratio. Our data call for functional analyses of putative cancer drivers to guide clinical application.


  • Open Access

    HNF1A recruits KDM6A to activate differentiated acinar cell programs that suppress pancreatic cancer

    by Mark Kalisz, Edgar Bernardo, Anthony Beucher, Miguel Angel Maestro, Natalia del Pozo, Irene Millán, Lena Haeberle, Martin Schlensog, Sami Alexander Safi, Wolfram Trudo Knoefel, et al.

    Defects in transcriptional regulators of pancreatic exocrine differentiation have been implicated in pancreatic tumorigenesis, but the molecular mechanisms are poorly understood. The locus encoding the transcription factor HNF1A harbors susceptibility variants for pancreatic ductal adenocarcinoma (PDAC), while KDM6A , encoding Lysine‐specific demethylase 6A, carries somatic mutations in PDAC. Here, we show that pancreas‐specific Hnf1a null mutant transcriptomes phenocopy those of Kdm6a mutations, and both defects synergize with Kras G12D to cause PDAC with sarcomatoid features. We combine genetic, epigenomic, and biochemical studies to show that HNF1A recruits KDM6A to genomic binding sites in pancreatic acinar cells. This remodels the acinar enhancer landscape, activates differentiated acinar cell programs, and indirectly suppresses oncogenic and epithelial–mesenchymal transition genes. We also identify a subset of non‐classical PDAC samples that exhibit the HNF1A/KDM6A ‐deficient molecular phenotype. These findings provide direct genetic evidence that HNF1A deficiency promotes PDAC. They also connect the tumor‐suppressive role of KDM6A deficiency with a cell‐specific molecular mechanism that underlies PDAC subtype definition.


  • Open Access

    HNF1A recruits UTX to activate a differentiation program that suppresses pancreatic cancer

    by Mark Kalisz, Edgar Bernardo, Anthony Beucher, Miguel Angel Maestro, Natalia del Pozo, Irene Millán, Lena Haeberle, Martin Schlensog, Sami Alexander Safi, Wolfram Trudo Knoefel, et al.

    Defects in transcriptional regulators of pancreatic exocrine differentiation have been implicated in pancreatic tumorigenesis, but the molecular mechanisms are poorly understood. The locus encoding the transcription factor HNF1A harbors susceptibility variants for pancreatic ductal adenocarcinoma (PDAC), while KDM6A , encoding the histone demethylase UTX, carries somatic mutations in PDAC. Here, we show that pancreas-specific Hnf1a null mutations phenocopy Utx deficient mutations, and both synergize with Kras G12D to cause PDAC with sarcomatoid features. We combine genetic, epigenomic and biochemical studies to show that HNF1A recruits UTX to genomic binding sites in pancreatic acinar cells. This remodels the acinar enhancer landscape, activates a differentiation program, and indirectly suppresses oncogenic and epithelial-mesenchymal transition genes. Finally, we identify a subset of non-classical PDAC samples that exhibit the HNF1A/UTX -deficient molecular phenotype. These findings provide direct genetic evidence that HNF1A-deficiency promotes PDAC. They also connect the tumor suppressive role of UTX deficiency with a cell-specific molecular mechanism that underlies PDAC subtype definition.